Contrasting of AC Immune SA (ACIU) and United Therapeutics Corporation (NASDAQ:UTHR)

Both AC Immune SA (NASDAQ:ACIU) and United Therapeutics Corporation (NASDAQ:UTHR) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AC Immune SA N/A 0.00 N/A -0.53 0.00
United Therapeutics Corporation 1.63B 3.24 589.20M 13.42 8.95

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of AC Immune SA and United Therapeutics Corporation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
AC Immune SA 0.00% -25.2% -22.4%
United Therapeutics Corporation 36.15% 22.5% 18%


The Current Ratio and Quick Ratio of AC Immune SA are 19.2 and 19.2 respectively. Its competitor United Therapeutics Corporation’s Current Ratio is 6.4 and its Quick Ratio is 6. AC Immune SA can pay off short and long-term obligations better than United Therapeutics Corporation.

Analyst Ratings

AC Immune SA and United Therapeutics Corporation Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AC Immune SA 0 0 0 0.00
United Therapeutics Corporation 2 3 2 2.29

Meanwhile, United Therapeutics Corporation’s consensus price target is $118.67, while its potential downside is -1.77%.

Institutional & Insider Ownership

Institutional investors held 32.2% of AC Immune SA shares and 0% of United Therapeutics Corporation shares. About 52.69% of AC Immune SA’s share are held by insiders. Competitively, 0.1% are United Therapeutics Corporation’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AC Immune SA 2.88% 12.62% -58.61% -45.67% -55.77% -50.9%
United Therapeutics Corporation 0.21% 4.15% 2.02% -4.41% 5.78% 10.3%

For the past year AC Immune SA has -50.9% weaker performance while United Therapeutics Corporation has 10.3% stronger performance.


United Therapeutics Corporation beats AC Immune SA on 10 of the 11 factors.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.